Patients & Caregivers

Our commitment to patients

We are committed to transforming the lives of patients and caregivers through our mission to develop improved treatment options for  immune-mediated diseases
A young woman sits outside on her laptop, smiling.
A young man sits on his couch as he looks outside through the window.
A middle aged couple are walking their dog outside in a field in cool weather.
A woman lying in a field of grass, looking relaxed and content.
Patients & Caregivers

Innovation INSPYRED by you

Spyre's investigational antibodies are engineered to improve on today’s standard of care – with the goal of getting more patients into deeper remission with therapies that can be delivered less frequently

Rethinking treatment of Immune-mediated diseases

We are committed to improving treatment options for patients with gastrointestinal and dermatological diseases, aiming to help enhance their quality of life while managing their conditions effectively. Our focus is on developing innovative therapies that target specific aspects of these diseases:

Ulcerative colitis icon

Ulcerative colitis

Ulcerative colitis icon

Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by inflammation in the colon and the rectum. Some symptoms may include bloody diarrhea, abdominal pain, bowel urgency, and frequent bowel movements. Approximately 1.3 million individuals in the U.S. have UC, with tens of thousands of new patients diagnosed annually. Despite recent advancements in treatment, a significant number of people living with UC continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission and a high frequency of injections that may lead to poor compliance.

Crohn’s disease icon

Crohn’s disease

Crohn’s disease icon

Crohn’s disease (CD) is a chronic inflammatory disorder characterized by inflammation in any part of the gastrointestinal tract, from the mouth to the rectum. Some symptoms may include abdominal pain, diarrhea, weight loss, fatigue, and complications such as strictures or fistulas. Approximately 1 million individuals in the U.S. have CD, with tens of thousands of new patients diagnosed annually. Despite recent advancements in treatment, a significant number of people living with CD continue to suffer from active disease. Today’s treatments are associated with many challenges, including low rates of remission and a high frequency of injections that may lead to poor compliance.

Ulcerative colitis icon

Hidradenitis suppurativa

Ulcerative colitis icon

Hidradenitis suppurativa (HS) is a chronic, immune-mediated inflammatory skin disease that primarily affects areas where skin rubs together, including the underarms, groin, and beneath the breasts. It is characterized by recurrent painful nodules and abscesses that can rupture, drain, form tunnels beneath the skin, and cause permanent scarring, often substantially affecting mobility, mental health, and quality of life. HS may affect approximately 3 million people in the U.S., although prevalence estimates vary widely and the disease is frequently undiagnosed or misdiagnosed. Despite recent advances in treatment, many people living with HS continue to experience active disease. Today’s treatments are associated with significant challenges, including incomplete or loss of response, a limited number of mechanisms of action to cycle through, frequent injections, prolonged antibiotic use, and the need for painful procedures or surgery to address irreversible tunnels and scarring.

Our Clinical Trials

Product candidates discussed below are investigational and currently being studied in clinical trials. Their safety and efficacy have not been established and they have not been approved for any use by FDA, the European Commission, or any other health authority.

See our expanded access policy

Phase 2 platform trial to test SPY001, SPY002, SPY003, and combination therapy in adults with moderate-to-severely active ulcerative colitis

This study will test the efficacy and safety of our long acting antibodies SPY001, SPY002, SPY003, and long acting combinations SPY120, SPY130, and SPY230 in adult patients with moderate-to-severely active ulcerative colitis. The study is anticipated to include a 12-week induction treatment period followed by a maintenance period.

Learn more

Phase 2 trial to test SPY072 in adults with moderate-to-severe HS on background SOC

This study will test the efficacy and safety of our long-acting antibody SPY072 versus placebo in adult patients with moderate-to-severely active HS who are on background SOC (bimekizumab). The study is anticipated to include a 16-week treatment period.

Learn more